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MECHANICAL CIRCULATORY SUPPORT FOR ONE THOUSAND DAYS OR MORE WITH THE NOVACOR
N100 LEFT VENTRICULAR ASSIST DEVICE
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Fig 1. Left ventricular diastolic (LVDVI) and systolic (LVSVI)
volume indices before implantation and after 11 and 28
months of implantation of the Novacor N100 LVAD.
On admission to the intensive care unit in April 1995, the
patient was having a period of acute cardiac decompensation
that could not be compensated with nitroglycerin, nitroprus-
side, diuretics, and catecholamines.
On May 26, 1995, a Novacor N100 LVAD was implanted
in the beating heart by the preperitoneal insertion technique.
The postoperative period was complicated by transient renal
failure, treated with continuous venovenous hemofiltration.
Additionally the patient’s recovery was complicated by
bronchopneumonia, which was managed with high doses of
antibiotics and antimycotics. A tracheostomy became neces-
sary because of prolonged ventilation. Eventually the patient
recovered progressively and was discharged to his home in
September 1995 in New York Heart Association (NYHA)
functional class I. The patient received training to monitor
his INR at home. The medications at discharge were
enalapril, acetylsalicylic acid, and phenprocoumon to main-
tain the INR between 3.0 and 3.5. Since then the patient has
been checked twice a week by phone and by a short hospital
stay every 6 months. During follow-up the recovery of left
ventricular function, aortic valve function, exclusion of
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The supply of donor hearts is inadequate to meet the needs
of patients with end-stage heart disease, so alternatives to
heart transplantation have been investigated. Surgical alterna-
tives are partial left ventriculectomy,1 cardiomyoplasty,2 use
of a total artificial heart, and implantation of a left ventricu-
lar assist device (LVAD). For mechanical support, the Jarvik
heart (Symbion, Inc, Salt Lake City, Utah) was initially
planned as a permanent application in patients who are
unsuitable candidates for heart transplantation.3
Because of the possible complications and the still imper-
fect system, one has to be very careful to identify patients for
permanent implantation of an LVAD.4 We report the case of
a patient who has been living at home for more than 3 years
with the Novacor portable LVAD (Baxter Healthcare Corp,
Novacor Div, Oakland, Calif).
Clinical summary. A 54-year-old man was admitted to our
hospital in April 1995 with severe congestive heart failure.
The diagnosis of dilated cardiomyopathy was made in 1989
at a local hospital. The patient’s other medical problems
included tuberculosis in 1970 and pneumonia in 1995.
Previous surgical interventions included an appendectomy in
1950 and a Billroth II operation in 1975 for a gastric ulcer;
another cardiac risk factor was smoking. His medications on
admission were enalapril, piretanide, spironolactone 50 mg,
digitoxin, diazepam, magnesium, and phenprocoumon with
an international normalized ratio (INR) between 3.0 and 3.5.
Clinical examination showed no sign of cyanosis or peripher-
al edema, a blood pressure of 90/60 mm Hg, and a heart rate
of 76 beats/min. By cardiac auscultation there was a holosys-
tolic murmur (grade 2/6) at the fifth intercostal space. A 1-
degree atrioventricular block was seen on the electrocardio-
gram. Transthoracic echocardiography and cardiac
catherterization showed grade 3 tricuspid regurgitation, grade
2 mitral regurgitation, grade 1 aortic regurgitation, pul-
monary hypertension (50 mm Hg), and global left ventricular
hypokinesia with a left ventricular ejection fraction of 8%.
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infections, and exclusion of intracardiac thrombus are evalu-
ated. Hemodynamic re-evaluation with cardiac catheteriza-
tion was done after 11, 19, and 28 months of implantation
(Fig 1). The device was routinely monitored by the Baxter
Novacor Division for mechanical dysfunction (Table I).
After more than 3 years of support with the Novacor N100
LVAD at full-rate trigger mode, the patient is doing well.
Clinically he is in NYHA class I, driving a car, and traveling
abroad for vacation.
Discussion. The surgical standard for end-stage cardiac
failure is heart transplantation if medical therapy fails. The 5-
year survival of patients undergoing cardiac transplantation is
about 60% to 70% and the mortality of patients waiting for
heart transplantation is between 20% and 30%, explained by
the shortage of available heart donors. A logical consequence
is the investigation of surgical treatments to offer patients
alternatives while awaiting heart transplantation, as well as
for patients excluded from transplantation. One of those alter-
natives is the wearable electrical LVAD. Because of the pro-
gressive failure of medical treatment, the Novacor LVAD was
implanted in this patient. Westaby5 reported recovery of
myocardial function during the first months after unloading
the left ventricle.
Inasmuch as our patient did not fulfill the weaning criteria,
he has to be supported permanently with close monitoring of
the device by energy converter, valve bioprostheses (and con-
duits), and acoustic characteristics, which in our patient are
still in excellent condition after more than 3 years. The most
readily retrievable data for monitoring the energy converter
bearings are the sensor tuning and fail-safe current changes.
The solenoid armatures tend to shift position as the main
bearings wear and develop slack. Because the solenoid sen-
sor flags are close to the main bearings, these shifts strongly
affect solenoid sensor tuning. Fill and eject rates are the pri-
mary data for assessing valve and conduit function. The sole-
noid inherently does not emit specific “chatter” frequencies
typical of rotary devices with worn bearings. However,
changes in sound level and acoustic spectral characteristics
may be useful for assessing degradation of pads, bearings,
and other parts.
During the past period of more than 1000 days of support,
we have observed no evidence of serious infection or throm-
boembolic complications.
Identifying the target population for permanent implanta-
tion of these devices includes patients who are excluded from
heart transplantation, alternative surgical options, or weaning
from the LVAD to increase their quality of life. More investi-
gation is needed to improve the assist devices, making them
more compact and totally implantable.
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Table I. Function control of the energy converter and valve prostheses (and conduits) from the Novacor LVAD
Energy converter Valves and conduits
Test date D Solenoid gain nSolenoid offset Fail safe current (A) Peak fill rate (mL/s) Peak ejection rate (mL/s)
April 1997 –5 –3 14.08 630 480
January 1998 –6 –2 14.24 690 472
May 1998 –1 0 14.56 512 490
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